Oxyntomodulin for preventing or treating excess weight

Details Oxyntomodulin for preventing or treating excess weight Oxyntomodulin for preventing or treating excess weight

2002-09-09

2010-02-23

Kosar, Andrew D (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07666835

ABSTRACT:
Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake.

REFERENCES:
patent: 4220653 (1980-09-01), Vivino
patent: 4698327 (1987-10-01), Nagarajan et al.
patent: 5432156 (1995-07-01), Matsuno et al.
patent: 5858975 (1999-01-01), Yano et al.
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6583111 (2003-06-01), DiMarchi et al.
patent: 6586403 (2003-07-01), Mathison et al.
patent: 7459432 (2008-12-01), Cowley et al.
patent: 2001/0011071 (2001-08-01), Knudsen et al.
patent: 2001/0046956 (2001-11-01), Hadcock
patent: 2002/0156010 (2002-10-01), Lustig
patent: 2004/0018975 (2004-01-01), DiMarchi et al.
patent: 2005/0070469 (2005-03-01), Bloom et al.
patent: 2005/0176630 (2005-08-01), Cowley et al.
patent: 2006/0014678 (2006-01-01), Cowley et al.
patent: 2006/0189522 (2006-08-01), Bloom et al.
patent: 2008/0064636 (2008-03-01), Bloom et al.
patent: 2009/0181885 (2009-07-01), Bloom
patent: 2009/0209461 (2009-08-01), Cowley et al.
patent: 0 619 332 (1994-10-01), None
patent: 0 795 562 (1997-09-01), None
patent: 03/026591 (2003-04-01), None
patent: 03/057235 (2003-07-01), None
patent: 2004/062685 (2004-07-01), None
patent: 2006/134340 (2006-12-01), None
patent: 2007/100535 (2007-09-01), None
patent: 2008/003947 (2008-01-01), None
patent: 2008/071972 (2008-06-01), None
H. E. Bays. Obesity Res. (2004) 12(8), pp. 1197-1211.
“The Wonders of Weight Loss” American Fitness. Jan./Feb. 2006, p. 18.
R. Parker. Internet document <http://www.futurepundit.com/archives/002946.html> Aug. 17, 2005, 4 pages; accessed Aug. 29, 2006.
J. Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241.
D.E. Smilek, et al. Proc. Natl. Acad. Sci. USA (1991) 88, pp. 9633-9637.
W.S. Messer, “Vasopressin and Oxytocin”, web document updated Apr. 3, 2000; <http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm>; 5 pages.
M.F. Wikosz and R.H. Bogner. US Pharmacist (2003) 28(4), 15 pages.
S. Senel and A.A. Hincal. J. Cont. Rel. (2001) 72, pp. 133-144.
B.T. Schjoldager, et al. Eur. J. Clin. Invest. (1988) 18(5), pp. 499-503.
“Oxyntomodulin” internet document <http://www.glucagon.com/oxyntomodulin.htm> Mar. 3, 2001, 2 pages; accessed Aug. 30, 2006.
Dakin et al., “Repeated ICV Administration of Oxyntomodulin Causes a Greater Reduction in Body Weight Gain Than in Pair-Fed Rats,”Am. J. Physiol. Endocrinol. Metab., 283:E1173-E1177, 2002.
Dakin et al., “Oxyntomodulin Inhibits Food Intake in the Rat,”Endocrinology, 142(10):4244-4250, 2001.
Uesaka et al., “Glucagon-Like Peptide Isolated from the Eel Intestine: Effects on Atrial Beating,”J. Exp. Biol., 204:3019-3026, 2001.
International Search Report for PCT/GB02/04082, mailed Jan. 23, 2003.
Assuncao, “Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine”,Rev. Bras. Psiquiatr., 28(4):270-276 (2006).
Garrow, “Does cimetidine cause weight loss?”,BMJ., 306(6885):1084 (1993).
Rasmussen, “Cimetidine suspension as adjuvant to energy restricted diet in treating obesity”,BMJ., 306(6885):1093-1096 (1993).
Stoa-Birketvedt, “Cimetidine reduces weight and improves metabolic control in overweight patients with Type 2 diabetes”,International Journal of Obesity Relat. Metab. Disord., 22(11):1041-1045 (1998).
Stoa-Birketvedt, “Effect of cimetidine suspension on appetite and weight in overweight subjects”,BMJ., 306(6885):1091-1093 (1993).
Stoa-Birketvedt, “H2-receptor antagonist reduces food intake and weight gain in rats by non-gastric acid secretory mechanisms”,Scandinavian Physiological Society, 161(4):489-494 (1997).
Walan and Ström, “Metabolic consequences of reduced gastric acidity”, Scand. J. Gastroenterol. Suppl., 111:24-30 (1985).
Andersen & Rasmussen “Cimetidine and obesity: Conflicting evidence” Intl. J. Obesity 23:550 (1999).
Bagger et al. “Nasal bioavailability of peptide T in rabbits: Absorption enhancement by sodium glycocholate and glycofurol” Eur. J. Pharm. Sci. 14:69-74 (2001).
Kawana et al. “Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies” Vaccine 19:1496-1502 (2001).
Tani et al. “Oxyntomodulin and related peptides control somatostatin secretion in RIN T3 cells” Biochim. Biophys. Acta 1095:249-254 (1991).
Tzotsas et al. “Use of somatostatin analogues in obesity” Drugs 68:1963-1973 (2008).
Wynne et al. “Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects” Diabetes 54:2390-2395 (2005).
Dakin et al. “Novel actions of oxyntomodulin in the central nervous system” J. Endocrinol., abstract supplement (19thJoint Meeting of the British Endocrine Societies, with the European Federation of Endocrine Societies—Mar. 13-16, 2000) 164(suppl):P181 (Mar. 2000).
P01275 (gi45644939): “Glucagon precursor”, GenBank Record dated Jan. 23, 2007, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on Jun. 9, 2007, retrieved from internet using <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=45644939>, GenBank Accession No. P01275 (gi45644939).
P01275 (gi121484): “Glucagon precursor”, GenBank Record dated Aug. 20, 2001, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on Jun. 9, 2007, retrieved from internet using <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?121484:)OLD09:43184>, GenBank Accession No. P01275 (gi121484).
P01273 (gi1346151): “Glucagon precursor”, GenBank Record dated Jul. 10, 2007, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on Jun. 9, 2007, retrieved from internet using <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=1346151>, GenBank Accession No. P01273 (gi1346151).
P01275: “GLUC—HUMAN”, ExPASy [online] Swiss Institute of Bioinformatics (SIB), Gasteiger E., Gattiker A., Hoogland C., Ivanyi I., Appel R.D., Bairoch A. ExPASy: the proteomics server for in-depth protein knowledge and analysis Nucleic Acids Res. 31:3784-3788(2003), retrieved on May 27, 2005, retrieved from internet using <URL:http://www.au.expasy.org/cgi-bin/sprot-ft-details.pl?P01275@PEPTIDE@53@89>, ExPASy Accession No. P01275.
P01272 (gi121479): “Glucagon precursor”, GenBank Record dated Aug. 21, 2007, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on Jun. 9, 2007, retrieved from internet using <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=121479>, GenBank Accession No. P01272 (gi121479).
P06883 (gi121496): “Glucagon precursor”, GenBank Record dated Jul. 10, 2007, (GenBank [online] Bethesda, MD USA: United States National Library of Medicine, retrieved on Jun. 9, 2007, retrieved from internet using <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=121496>, GenBank Accession No. P06883 (gi121496).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”, Science, vol. 247, pp. 1306-1310, Mar. 16, 1990.
“Novel Actions of Oxyntomodulin in the Central Nervous System”, CL Dakin et al., Dept. of Endocrinology & Metabolism, Imperial College School Medicine, Hammersmith Hospital, Du Cane Road, London. W12 ONN, Journal of Endocrinology, Mar. 2000, vol. 164 Supplement (Abstract #181).
“Novel Actions of Oxyntomodulin in the Central Nervous System”, CL Dakin et al., Dept. of Endocri

Affiliated with

Also associated with

Rating

Oxyntomodulin for preventing or treating excess weight does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oxyntomodulin for preventing or treating excess weight, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxyntomodulin for preventing or treating excess weight will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4190539